Skip to main content

Table 3 Odds ratios and 95% confidence intervals for association individual and concurrent metabolic comorbidities and risks of recurrent metastatic disease using binominal logistic regression, N = 1081. Individual and concurrent metabolic variables were included in the multivariable analysis

From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors

Presence of metabolic comorbidities With distant metastasis event
N (%)
Without distant metastasis event N (%) OR 95%CI P value
DM or glucose intolerance 90 (32%) 197 (24.6%) 1.442 1.071–1.943 0.016
Dyslipidemia 78 (27.7%) 221 (27.6%) 1.007 0.746–1.364 0.966
Hypertension 118 (41.9%) 346 (43.25%) 0.950 0.721–1.251 0.714
BMI risk 66 (23.5%) 186 (23.2%) 1.013 0.735–1.397 0.935
DM/glucose intolerance + Dyslipidemia 51 (18.1%) 96 (12.0%) 1.626 1.122–2.356 0.010
DM/glucose intolerance + Hypertension 76 (27.0%) 159 (19.9%) 1.495 1.090–2.049 0.013
Dyslipidemia + Hypertension 75 (26.7%) 204 (25.5%) 1.064 0.781–1.448 0.695
Dyslipidemia + BMI risk 32 (11.4%) 93 (11.6%) 0.977 0.638–1.497 0.915
Hypertension + BMI risk 45 (16.0%) 125 (15.6%) 1.030 0.710–1.493 0.877
DM/glucose intolerance + BMI risk 23 (8.2%) 59 (7.4%) 1.120 0.678–1.850 0.678
≥3 metabolic comorbidities 77 (27.4%) 151 (18.9%) 1.622 1.182–2.226 0.003
Any metabolic comorbidity 146 (53.6%) 460 (56.7%) 0.875 0.664–1.152 0.341